Scholarlink

<p>Glucagon-like peptide&#xa0;1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase&#xa0;4 inhibitors (DPP-4is) are well-established agents for type&#xa0;2 diabetes mellitus (T2DM) management. Ongoing research has provided data on their both beneficial and adverse effects on the skin. For instance, GLP-1RAs have exhibited therapeutic benefits&#xa0;in psoriasis, while DPP-4is may reduce the risk of melanoma.&#xa0;Moreover, both of these agents may play a pivotal role in improving wound healing. However,&#xa0;untoward effects, such as bullous pemphigoid, highlight the need for&#xa0;patient monitoring. This review summarises the beneficial and adverse effects of GLP-1RAs and DPP-4is in dermatological conditions and in systemic diseases with cutaneous manifestations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin—Diabetes Meets Dermatology: A Brief Narrative Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Dimitrios Pantazopoulos,
  • Evanthia Gouveri,
  • Massimo Papi,
  • Dimitrios Papazoglou,
  • Nikolaos Papanas

摘要

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is) are well-established agents for type 2 diabetes mellitus (T2DM) management. Ongoing research has provided data on their both beneficial and adverse effects on the skin. For instance, GLP-1RAs have exhibited therapeutic benefits in psoriasis, while DPP-4is may reduce the risk of melanoma. Moreover, both of these agents may play a pivotal role in improving wound healing. However, untoward effects, such as bullous pemphigoid, highlight the need for patient monitoring. This review summarises the beneficial and adverse effects of GLP-1RAs and DPP-4is in dermatological conditions and in systemic diseases with cutaneous manifestations.